(Administrative Core) This renewal application aims to continue research on rare eosinophilic gastrointestinal diseases (EGIDs) with a focus on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC) through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).
CEGIR aims to promote highly collaborative, multi-site, patient-centric, translational and clinical research with the intent of addressing unmet clinical trial readiness needs. Though still in a relatively early stage, CEGIR is demonstrating success via its collaborative interactions between investigators (at all stages of career development), proactive patient advocacy groups (PAGs), and partnering institutions at the NIH and has emerged into the leading clinical and research group focused on rare EGIDs. The CEGIR Administrative Core aims to effectively generate and administer the policies, procedures, communications, and funds associated with CEGIR and ensure that the highest level of rigor, at all levels including scientific, is achieved. The CEGIR Administrative Core will be integral in coordinating decision-making and implementation to achieve the objectives of CEGIR. The CEGIR Administrative Core will include the CEGIR Director (Principal Investigator), Clinical Trial Liaison, and the CEGIR Internal Steering Committee. The CEGIR Internal Steering Committee will be composed of the Site Leaders, PAG representatives [i.e., American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Diseases (CURED), Eosinophilic Family Coalition (EFC)], and Administrative Coordinators. Specific activities of the CEGIR Administrative Core include but are not limited to the following: 1) generate and administer research policies; 2) administer and monitor budgets and fund distribution; 3) provide oversight and guidance for CEGIR Cores and Committees; 4) review and distribute reports and proceedings from CEGIR Cores and Committees to appropriate audiences (e.g., stakeholders); 5) disseminate web-based information as per National Institutes of Health (NIH) guidelines and directives; 6) integrate valuable insight from the External Advisory Committee (EAC); and 7) foster integration and partnership with PAGs, other Rare Diseases Research Consortia, and stakeholders, including international liaisons. The Administrative Core will manage CEGIR operations ensuring that CEGIR achieves its goals in efficient, productive, and successful manners.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI117804-07
Application #
10019463
Study Section
Special Emphasis Panel (ZTR1)
Project Start
2014-08-15
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20
Fahey, Lisa M; Chandramouleeswaran, Prasanna M; Guan, Shaobo et al. (2018) Food allergen triggers are increased in children with the TSLP risk allele and eosinophilic esophagitis. Clin Transl Gastroenterol 9:139
Wechsler, Joshua B; Bolton, Scott M; Amsden, Katie et al. (2018) Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. Clin Gastroenterol Hepatol 16:1056-1063
Spergel, Jonathan M; Aceves, Seema S; Kliewer, Kara et al. (2018) New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting. J Allergy Clin Immunol 142:48-53
Pesek, Robert D; Gupta, Sandeep K (2018) Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs 23:173-183
Schwartz, Justin T; Morris, David W; Collins, Margaret H et al. (2018) Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. J Allergy Clin Immunol :
Mark, Jacob; Fernando, Shahan D; Masterson, Joanne C et al. (2018) Clinical Implications of Pediatric Colonic Eosinophilia. J Pediatr Gastroenterol Nutr 66:760-766
Nguyen, N; Fernando, S D; Biette, K A et al. (2018) TGF-?1 alters esophageal epithelial barrier function by attenuation of claudin-7 in eosinophilic esophagitis. Mucosal Immunol 11:415-426
Ferguson, Anna E; Mukkada, Vince A; Fulkerson, Patricia C (2018) Pediatric Eosinophilic Esophagitis Endotypes: Are We Closer to Predicting Treatment Response? Clin Rev Allergy Immunol 55:43-55
Hill, David A; Grundmeier, Robert W; Ramos, Mark et al. (2018) Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. J Allergy Clin Immunol Pract 6:1528-1533

Showing the most recent 10 out of 103 publications